Evonik Evonik

X

Find GC4711 manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

EU WC

EU WC

0

Listed Suppliers

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

GC4711
Also known as: Gc-4419 dipropionate, Bis-propionato(gc4419), Fw5t90vm32, Gc4711, Gc-4711, Rucosopasem manganese
Molecular Formula
C27H45MnN5O4
Molecular Weight
558.6  g/mol
InChI Key
AVSNGWGGPXFPQX-NDOCQCNASA-L
FDA UNII
FW5T90VM32

Rucosopasem Manganese is a mimetic of the enzyme superoxide dismutase (SOD) that may potentially be used to increase the anti-cancer efficacy of stereotactic body radiation therapy (SBRT). Upon administration, rucosopasem manganese may mimic native SODs and catalyze the formation of molecular oxygen and hydrogen peroxide from the burst of superoxide anion present in the irradiated tissues upon radiation. As hydrogen peroxide is less toxic than superoxide to normal tissues, but more toxic to cancer cells, this may increase the anti-cancer efficacy of SBRT and decrease its damage to normal tissues.
1 2D Structure

GC4711

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
manganese(2+);(4S,9S,14S,19S)-3,10,13,20,26-pentazatetracyclo[20.3.1.04,9.014,19]hexacosa-1(26),22,24-triene;propanoate
2.1.2 InChI
InChI=1S/C21H35N5.2C3H6O2.Mn/c1-3-10-20-18(8-1)22-12-13-23-19-9-2-4-11-21(19)25-15-17-7-5-6-16(26-17)14-24-20;2*1-2-3(4)5;/h5-7,18-25H,1-4,8-15H2;2*2H2,1H3,(H,4,5);/q;;;+2/p-2/t18-,19-,20-,21-;;;/m0.../s1
2.1.3 InChI Key
AVSNGWGGPXFPQX-NDOCQCNASA-L
2.1.4 Canonical SMILES
CCC(=O)[O-].CCC(=O)[O-].C1CCC2C(C1)NCCNC3CCCCC3NCC4=CC=CC(=N4)CN2.[Mn+2]
2.1.5 Isomeric SMILES
CCC(=O)[O-].CCC(=O)[O-].C1CC[C@H]2[C@H](C1)NCCN[C@H]3CCCC[C@@H]3NCC4=CC=CC(=N4)CN2.[Mn+2]
2.2 Other Identifiers
2.2.1 UNII
FW5T90VM32
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Gc-4419 Dipropionate

2. Bis-propionato(gc4419)

3. Fw5t90vm32

4. Gc4711

5. Gc-4711

6. Rucosopasem Manganese

7. Manganese(ii), Bis-propionato((4as,13as,17as,21as)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7h-dibenzo(b,h)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,

8. 2081067-45-8

9. Unii-fw5t90vm32

10. Rucosopasem Manganese [inn]

11. 2248030-85-3

12. Manganese, ((4as,13as,17as,21as)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7h-dibenzo(b,h)(1,4,7,10)tetraazacycloheptadecine-.kappa.n5,.kappa.n13,.kappa.n18,.kappa.n21,.kappa.n22)bis(propanoato-.kappa.o)-, (pb-7-11-2344'3')

2.4 Create Date
2017-10-17
3 Chemical and Physical Properties
Molecular Weight 558.6 g/mol
Molecular Formula C27H45MnN5O4
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count9
Rotatable Bond Count0
Exact Mass558.285198 g/mol
Monoisotopic Mass558.285198 g/mol
Topological Polar Surface Area141 Ų
Heavy Atom Count37
Formal Charge0
Complexity416
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count4
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY